Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amuvatinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT known ✓ | P10721 | 6/20 | 1.00 |
| ▸ | PDGFRA known ✓ | P16234 | 4/20 | 1.00 |
| ▸ | FLT3 known ✓ | P36888 | 2/20 | 0.98 |
| ▸ | LMNA | P02545 | 4/20 | 0.70 |
| ▸ | TSHR | P16473 | 4/20 | 0.70 |
| ▸ | HTT | P42858 | 3/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.70 |
| ▸ | MAPT | P10636 | 3/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.61 |
| ▸ | KDR | P35968 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | HRH1 | P35367 | 1/20 | 0.52 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amuvatinib SCHEMBL29351463 | 1.00 | KIT (1.00) | KITPDGFRAFLT3LMNATSHR | |
| Amuvatinib SCHEMBL29431554 | 1.00 | KIT (1.00) | KITPDGFRAFLT3LMNATSHR | |
| Amuvatinib SCHEMBL1686091 | 0.99 | KIT (1.00) | KITPDGFRAFLT3LMNATSHR | |
| Amuvatinib SCHEMBL29883318 | 0.99 | KIT (1.00) | KITPDGFRAFLT3LMNATSHR | |
| SCHEMBL13771287 | 0.87 | KIT (0.77) | KITPDGFRAFLT3LMNATSHR | |
| SCHEMBL14273845 | 0.86 | KIT (0.76) | KITPDGFRAFLT3LMNATSHR | |
| SCHEMBL12306944 | 0.86 | KIT (0.76) | KITPDGFRAFLT3LMNATSHR | |
| SCHEMBL24293505 | 0.86 | KIT (0.75) | KITPDGFRAFLT3LMNATSHR | |
| SCHEMBL12256008 | 0.85 | LMNA (0.86) | KITPDGFRAFLT3LMNATSHR | |
| SCHEMBL14298731 | 0.85 | KIT (0.74) | KITPDGFRAFLT3LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024200612-A1 | INHIBITORS OF URIDINE CATABOLISM AND/OR TRANSPORT FOR THERAPY | Université de Lausanne (CH) | 2024-10-03 | — | — | WO | claimed |
| US-20230250169-A1 | AXL Inhibitors for Antiviral Therapy | BERGENBIO ASA (NO) | 2023-08-10 | — | — | US | claimed |
| US-20230151100-A1 | Method of Selecting Patients for Treatment with a Combination of an AXL Inhibitor and an Immune Checkpoint Modulator | BERGENBIO ASA (NO) | 2023-05-18 | — | — | US | claimed |
| CN-116075303-A | Method of selecting patients treated with a combination of an AXL inhibitor and an immune checkpoint modulator | 卑尔根生物股份公司 | 2023-05-05 | — | — | CN | claimed |
| CN-115916344-A | AXL inhibitors for antiviral therapy | 卑尔根生物股份公司 | 2023-04-04 | — | — | CN | claimed |
| EP-4138823-A1 | METHOD OF SELECTING PATIENTS FOR TREATMENT WITH A COMBINATION OF AN AXL INHIBITOR AND AN IMMUNE CHECKPOINT MODULATOR | BerGenBio ASA (NO) | 2023-03-01 | — | — | EP | claimed |
| EP-4132652-A1 | AXL INHIBITORS FOR ANTIVIRAL THERAPY | BerGenBio ASA (NO) | 2023-02-15 | — | — | EP | claimed |
| EP-4125908-A1 | COMBINATION THERAPY COMPRISING AN AXL INHIBITOR | BerGenBio ASA (NO) | 2023-02-08 | — | — | EP | claimed |
| WO-2021214492-A1 | METHOD OF SELECTING PATIENTS FOR TREATMENT WITH A COMBINATION OF AN AXL INHIBITOR AND AN IMMUNE CHECKPOINT MODULATOR | BERGENBIO ASA (NO) | 2021-10-28 | — | — | WO | claimed |
| WO-2021191197-A1 | COMBINATION THERAPY COMPRISING AN AXL INHIBITOR | BERGENBIO ASA (NO) | 2021-09-30 | — | — | WO | claimed |
| WO-2021032883-A1 | COMBINATION THERAPY OF A PATIENT SUBGROUP | BERGENBIO ASA (NO) | 2021-02-25 | — | — | WO | claimed |
| EP-2425830-A1 | Synergistic drug combination for the treatment of cancer | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2012-03-07 | — | — | EP | claimed |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| EP-4558505-A2 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | Schrödinger, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| EP-4543449-A1 | DOSAGE REGIMEN FOR AXL INHIBITOR | BerGenBio ASA (NO) | 2025-04-30 | — | — | EP | disclosed |
| WO-2025059027-A1 | CYCLOPENTA[E]PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AS MALT1 INHIBITORS | SCHRÖDINGER, INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| US-7326712-B2 | Substituted tricyclic compounds as protein kinase inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2008-02-05 | — | — | US | disclosed |
| US-7326712-B2 | Substituted tricyclic compounds as protein kinase inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2008-02-05 | — | — | US | disclosed |
| US-7312226-B2 | Substituted tricyclic compounds as protein kinase inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312226-B2 | Substituted tricyclic compounds as protein kinase inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2007-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250169-A1 | AXL Inhibitors for Antiviral Therapy | FLT3, AXL, SARS1 | KIT 1463/4885PDGFRA 704/4885FLT3 1/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | KIT 2410/4885PDGFRA 2974/4885FLT3 4879/4885 |
| US-20230151100-A1 | Method of Selecting Patients for Treatment with a Combination of an AXL Inhibitor and an Immune Checkpoint Modulator | STK11, MERTK, AXL | KIT 890/4885PDGFRA 876/4885FLT3 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.